Center-Authored Papers

Filters: Author is Litzow, Mark R  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
Young Adult
Ringdén O, Pavletic SZ, Anasetti C, Barrett JA, Wang T, Wang D, Antin JH, Di Bartolomeo P, Bolwell BJ, Bredeson C et al..  2009.  The graft-versus-leukemia effect using matched unrelated donors is not superior to HLA-identical siblings for hematopoietic stem cell transplantation.. Blood. 113(13):3110-8. Abstract
Copelan EA, Hamilton BK, Avalos B, Woo Ahn K, Bolwell BJ, Zhu X, Aljurf M, van Besien K, Bredeson C, Cahn J-Y et al..  2013.  Better leukemia-free and overall survival in AML in first remission following cyclophosphamide in combination with busulfan compared with TBI.. Blood. 122(24):3863-70. Abstract
Whole-Body Irradiation
Copelan EA, Hamilton BK, Avalos B, Woo Ahn K, Bolwell BJ, Zhu X, Aljurf M, van Besien K, Bredeson C, Cahn J-Y et al..  2013.  Better leukemia-free and overall survival in AML in first remission following cyclophosphamide in combination with busulfan compared with TBI.. Blood. 122(24):3863-70. Abstract
Vidarabine
Smith MR, Neuberg D, Flinn IW, Grever MR, Lazarus HM, Rowe JM, Dewald G, Bennett JM, Paietta EM, Byrd JC et al..  2011.  Incidence of Therapy-related Myeloid Neoplasia after Initial Therapy for CLL with Fludarabine-Cyclophosphamide versus Fludarabine: Long-Term Follow-up of US Intergroup Study E2997.. Blood. 118(3):3525-3527. Abstract
Unrelated Donors
Copelan EA, Hamilton BK, Avalos B, Woo Ahn K, Bolwell BJ, Zhu X, Aljurf M, van Besien K, Bredeson C, Cahn J-Y et al..  2013.  Better leukemia-free and overall survival in AML in first remission following cyclophosphamide in combination with busulfan compared with TBI.. Blood. 122(24):3863-70. Abstract
United States
Smith MR, Neuberg D, Flinn IW, Grever MR, Lazarus HM, Rowe JM, Dewald G, Bennett JM, Paietta EM, Byrd JC et al..  2011.  Incidence of Therapy-related Myeloid Neoplasia after Initial Therapy for CLL with Fludarabine-Cyclophosphamide versus Fludarabine: Long-Term Follow-up of US Intergroup Study E2997.. Blood. 118(3):3525-3527. Abstract
Treatment Outcome
Lee SJ, Kukreja M, Wang T, Giralt SA, Szer J, Arora M, Woolfrey AE, Cervantes F, Champlin RE, Gale RP et al..  2008.  Impact of prior imatinib mesylate on the outcome of hematopoietic cell transplantation for chronic myeloid leukemia.. Blood. 112(8):3500-7. Abstract
Copelan EA, Hamilton BK, Avalos B, Woo Ahn K, Bolwell BJ, Zhu X, Aljurf M, van Besien K, Bredeson C, Cahn J-Y et al..  2013.  Better leukemia-free and overall survival in AML in first remission following cyclophosphamide in combination with busulfan compared with TBI.. Blood. 122(24):3863-70. Abstract
Transplantation, Homologous
Copelan EA, Hamilton BK, Avalos B, Woo Ahn K, Bolwell BJ, Zhu X, Aljurf M, van Besien K, Bredeson C, Cahn J-Y et al..  2013.  Better leukemia-free and overall survival in AML in first remission following cyclophosphamide in combination with busulfan compared with TBI.. Blood. 122(24):3863-70. Abstract
Tissue Donors
Ringdén O, Pavletic SZ, Anasetti C, Barrett JA, Wang T, Wang D, Antin JH, Di Bartolomeo P, Bolwell BJ, Bredeson C et al..  2009.  The graft-versus-leukemia effect using matched unrelated donors is not superior to HLA-identical siblings for hematopoietic stem cell transplantation.. Blood. 113(13):3110-8. Abstract
Time Factors
Smith MR, Neuberg D, Flinn IW, Grever MR, Lazarus HM, Rowe JM, Dewald G, Bennett JM, Paietta EM, Byrd JC et al..  2011.  Incidence of Therapy-related Myeloid Neoplasia after Initial Therapy for CLL with Fludarabine-Cyclophosphamide versus Fludarabine: Long-Term Follow-up of US Intergroup Study E2997.. Blood. 118(3):3525-3527. Abstract
Copelan EA, Hamilton BK, Avalos B, Woo Ahn K, Bolwell BJ, Zhu X, Aljurf M, van Besien K, Bredeson C, Cahn J-Y et al..  2013.  Better leukemia-free and overall survival in AML in first remission following cyclophosphamide in combination with busulfan compared with TBI.. Blood. 122(24):3863-70. Abstract
Telomere Homeostasis
Baljevic M, Dumitriu B, Lee J-W, Paietta EM, Wiernik PH, Racevskis J, Chen C, Stein EM, Gallagher RE, Rowe JM et al..  2016.  Telomere Length Recovery: A Strong Predictor of Overall Survival in Acute Promyelocytic Leukemia.. Acta haematologica. 136(4):210-218. Abstract
TELOMERASE
Baljevic M, Dumitriu B, Lee J-W, Paietta EM, Wiernik PH, Racevskis J, Chen C, Stein EM, Gallagher RE, Rowe JM et al..  2016.  Telomere Length Recovery: A Strong Predictor of Overall Survival in Acute Promyelocytic Leukemia.. Acta haematologica. 136(4):210-218. Abstract
Survival Rate
Baljevic M, Dumitriu B, Lee J-W, Paietta EM, Wiernik PH, Racevskis J, Chen C, Stein EM, Gallagher RE, Rowe JM et al..  2016.  Telomere Length Recovery: A Strong Predictor of Overall Survival in Acute Promyelocytic Leukemia.. Acta haematologica. 136(4):210-218. Abstract
Siblings
Copelan EA, Hamilton BK, Avalos B, Woo Ahn K, Bolwell BJ, Zhu X, Aljurf M, van Besien K, Bredeson C, Cahn J-Y et al..  2013.  Better leukemia-free and overall survival in AML in first remission following cyclophosphamide in combination with busulfan compared with TBI.. Blood. 122(24):3863-70. Abstract
Ringdén O, Pavletic SZ, Anasetti C, Barrett JA, Wang T, Wang D, Antin JH, Di Bartolomeo P, Bolwell BJ, Bredeson C et al..  2009.  The graft-versus-leukemia effect using matched unrelated donors is not superior to HLA-identical siblings for hematopoietic stem cell transplantation.. Blood. 113(13):3110-8. Abstract
September 2011
Smith MR, Neuberg D, Flinn IW, Grever MR, Lazarus HM, Rowe JM, Dewald G, Bennett JM, Paietta EM, Byrd JC et al..  2011.  Incidence of Therapy-related Myeloid Neoplasia after Initial Therapy for CLL with Fludarabine-Cyclophosphamide versus Fludarabine: Long-Term Follow-up of US Intergroup Study E2997.. Blood. 118(3):3525-3527. Abstract
Armand P, Kim HT, Zhang M-J, Perez WS, Dal Cin PS, Klumpp TR, Waller EK, Litzow MR, Liesveld JL, Lazarus HM et al..  2012.  Classifying Cytogenetics in Patients with Acute Myelogenous Leukemia in Complete Remission Undergoing Allogeneic Transplantation: A Center for International Blood and Marrow Transplant Research Study.. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 18(2):280-288. Abstract
RNA
Baljevic M, Dumitriu B, Lee J-W, Paietta EM, Wiernik PH, Racevskis J, Chen C, Stein EM, Gallagher RE, Rowe JM et al..  2016.  Telomere Length Recovery: A Strong Predictor of Overall Survival in Acute Promyelocytic Leukemia.. Acta haematologica. 136(4):210-218. Abstract
Research Trials Office Core Facility - Biostatistics Service
Lee SJ, Storer B, Wang H, Lazarus HM, Waller EK, Isola LM, Klumpp TR, Umejiego JBC, Savani BN, Loren AW et al..  2013.  Providing personalized prognostic information for adult leukemia survivors.. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 19(11):1600-7. Abstract
Remission Induction
Copelan EA, Hamilton BK, Avalos B, Woo Ahn K, Bolwell BJ, Zhu X, Aljurf M, van Besien K, Bredeson C, Cahn J-Y et al..  2013.  Better leukemia-free and overall survival in AML in first remission following cyclophosphamide in combination with busulfan compared with TBI.. Blood. 122(24):3863-70. Abstract
Registries
Lee SJ, Kukreja M, Wang T, Giralt SA, Szer J, Arora M, Woolfrey AE, Cervantes F, Champlin RE, Gale RP et al..  2008.  Impact of prior imatinib mesylate on the outcome of hematopoietic cell transplantation for chronic myeloid leukemia.. Blood. 112(8):3500-7. Abstract
Pyrimidines
Lee SJ, Kukreja M, Wang T, Giralt SA, Szer J, Arora M, Woolfrey AE, Cervantes F, Champlin RE, Gale RP et al..  2008.  Impact of prior imatinib mesylate on the outcome of hematopoietic cell transplantation for chronic myeloid leukemia.. Blood. 112(8):3500-7. Abstract
Polymorphism, Genetic
Baljevic M, Dumitriu B, Lee J-W, Paietta EM, Wiernik PH, Racevskis J, Chen C, Stein EM, Gallagher RE, Rowe JM et al..  2016.  Telomere Length Recovery: A Strong Predictor of Overall Survival in Acute Promyelocytic Leukemia.. Acta haematologica. 136(4):210-218. Abstract